Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03051659 |
|---|---|
| Brief Title: | A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer |
| First Submitted : | February 8, 2017 |
| First Submitted that Met QC Criteria : | February 9, 2017 |
| First Posted : | February 14, 2017 |
| Last Update Submitted that Met QC Criteria : | April 25, 2020 |
| Last Update Posted : | April 28, 2020 |